110 related articles for article (PubMed ID: 26305669)
1. Cyclophilin A as a potential genetic adjuvant to improve HIV-1 Gag DNA vaccine immunogenicity by eliciting broad and long-term Gag-specific cellular immunity in mice.
Hou J; Zhang Q; Liu Z; Wang S; Li D; Liu C; Liu Y; Shao Y
Hum Vaccin Immunother; 2016; 12(2):545-53. PubMed ID: 26305669
[TBL] [Abstract][Full Text] [Related]
2. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.
Kanagavelu SK; Snarsky V; Termini JM; Gupta S; Barzee S; Wright JA; Khan WN; Kornbluth RS; Stone GW
Vaccine; 2012 Jan; 30(4):691-702. PubMed ID: 22146759
[TBL] [Abstract][Full Text] [Related]
3. A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract.
Ruane D; Do Y; Brane L; Garg A; Bozzacco L; Kraus T; Caskey M; Salazar A; Trumpheller C; Mehandru S
Mucosal Immunol; 2016 Sep; 9(5):1340-52. PubMed ID: 26732678
[TBL] [Abstract][Full Text] [Related]
4. The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein.
Braaten D; Ansari H; Luban J
J Virol; 1997 Mar; 71(3):2107-13. PubMed ID: 9032343
[TBL] [Abstract][Full Text] [Related]
5. A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target.
Appledorn DM; Aldhamen YA; Depas W; Seregin SS; Liu CJ; Schuldt N; Quach D; Quiroga D; Godbehere S; Zlatkin I; Kim S; McCormick JJ; Amalfitano A
PLoS One; 2010 Mar; 5(3):e9579. PubMed ID: 20221448
[TBL] [Abstract][Full Text] [Related]
6. Expression of the SLAM family of receptors adapter EAT-2 as a novel strategy for enhancing beneficial immune responses to vaccine antigens.
Aldhamen YA; Appledorn DM; Seregin SS; Liu CJ; Schuldt NJ; Godbehere S; Amalfitano A
J Immunol; 2011 Jan; 186(2):722-32. PubMed ID: 21149608
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1.
Sasaki S; Fukushima J; Hamajima K; Ishii N; Tsuji T; Xin KQ; Mohri H; Okuda K
Clin Exp Immunol; 1998 Jan; 111(1):30-5. PubMed ID: 9472658
[TBL] [Abstract][Full Text] [Related]
8. Influence of gag on human immunodeficiency virus type 1 species-specific tropism.
Ikeda Y; Ylinen LM; Kahar-Bador M; Towers GJ
J Virol; 2004 Nov; 78(21):11816-22. PubMed ID: 15479823
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant effect of dendritic cells activator Imiquimod in genetic immunization with HIV-1 p55 Gag.
Alves JM; Inyushin M; Tsytsarev V; Roldan-Kalil JA; Miranda-Valentin E; Maldonado-Martinez G; Ramos-Feliciano KM; Hunter-Mellado R
J Immunol Tech Infect Dis; 2023; 12(1):. PubMed ID: 37205236
[TBL] [Abstract][Full Text] [Related]
10. Virus specificity and nucleoporin requirements for MX2 activity are affected by GTPase function and capsid-CypA interactions.
Layish B; Goli R; Flick H; Huang SW; Zhang RZ; Kvaratskhelia M; Kane M
bioRxiv; 2023 Nov; ():. PubMed ID: 38014352
[TBL] [Abstract][Full Text] [Related]
11. The Mechanism and Potential Therapeutic Effects of Cyclosporin, Cyclophilin, Probiotics and Syndecan-1 in an Animal Model of Inflammatory Bowel Disease.
Dosh L; Rappa F; Jurjus A; Karam G; Lezeik R; El Masri J; Bucchieri F; Leone A; Jurjus R
Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38276500
[No Abstract] [Full Text] [Related]
12. The Role of Recombinant Human Cyclophilin A in the Antitumor Immune Response.
Kalinina AA; Silaeva YY; Kazansky DB; Khromykh LM
Acta Naturae; 2019; 11(2):63-67. PubMed ID: 31413881
[TBL] [Abstract][Full Text] [Related]
13. Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.
Ringe RP; Yasmeen A; Ozorowski G; Go EP; Pritchard LK; Guttman M; Ketas TA; Cottrell CA; Wilson IA; Sanders RW; Cupo A; Crispin M; Lee KK; Desaire H; Ward AB; Klasse PJ; Moore JP
J Virol; 2015 Dec; 89(23):12189-210. PubMed ID: 26311893
[TBL] [Abstract][Full Text] [Related]
14. Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
Ghosh AK; Martyr CD; Osswald HL; Sheri VR; Kassekert LA; Chen S; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
J Med Chem; 2015 Sep; 58(17):6994-7006. PubMed ID: 26306007
[TBL] [Abstract][Full Text] [Related]
15. Mutations in CypA Binding Region of HIV-1 Capsid Affect Capsid Stability and Viral Replication in Primary Macrophages.
Setiawan LC; van Dort KA; Rits MA; Kootstra NA
AIDS Res Hum Retroviruses; 2016 Apr; 32(4):390-8. PubMed ID: 26414211
[TBL] [Abstract][Full Text] [Related]
16. Impact of TRIM5α in vivo.
Nakayama EE; Shioda T
AIDS; 2015 Sep; 29(14):1733-43. PubMed ID: 26372380
[TBL] [Abstract][Full Text] [Related]
17. FAITH - Fast Assembly Inhibitor Test for HIV.
Hadravová R; Rumlová M; Ruml T
Virology; 2015 Dec; 486():78-87. PubMed ID: 26410239
[TBL] [Abstract][Full Text] [Related]
18. Natural Polymorphisms and Oligomerization of Human APOBEC3H Contribute to Single-stranded DNA Scanning Ability.
Feng Y; Love RP; Ara A; Baig TT; Adolph MB; Chelico L
J Biol Chem; 2015 Nov; 290(45):27188-27203. PubMed ID: 26396192
[TBL] [Abstract][Full Text] [Related]
19. A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins.
Suryawanshi GW; Hoffmann A
J Theor Biol; 2015 Dec; 386():89-104. PubMed ID: 26385832
[TBL] [Abstract][Full Text] [Related]
20. Disruption of Type I Interferon Induction by HIV Infection of T Cells.
Sanchez DJ; Miranda D; Marsden MD; Dizon TM; Bontemps JR; Davila SJ; Del Mundo LE; Ha T; Senaati A; Zack JA; Cheng G
PLoS One; 2015; 10(9):e0137951. PubMed ID: 26375588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
